60th Annual Meeting of the American Association for the Study of Liver Diseases

60th Annual Meeting of the American
Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2009



* Early Viral Response Rates in Treatment-naïve Patients with Chronic Hepatitis C Genotype 1 Infection Treated with MK-7009, a Novel NS3/4a Protease Inhibitor, in Combination with Pegylated Interferon Alfa-2a and Ribavirin for 28 Days - (11/05/09)

* Safety and Antiviral Activity of NS5B Polymerase Inhibitor MK-3281in Genotype 1 and 3 HCV-Infected Patients - (11/05/09)

* COMBINATION THERAPY WITH NUCLEOSIDE POLYMERASE (RG7128) AND PROTEASE (RG7227) INHIBITORS IN GENOTYPE 1 HCV INFECTED PATIENTS: INTERIM RESISTANCE ANALYSIS OF INFORM-1 COHORTS A-D - (11/05/09)

* Antiviral activity and safety of TMC435 combined with pegylated interferon and ribavirin in hepatitis C patients with genotype 1 who had previous exposure to TMC435 - (11/05/09)

* A Phase 1b Dose-Ranging Study of 4 Weeks of PEG-Interferon (IFN) Lambda (PEG-rIL-29) in Combination with Ribavirin (RBV) in Patients with Chronic Genotype 1 Hepatitis C Virus (HCV) Infection - (11/05/09)

* Antiviral Activity, Pharmacokinetics, Safety, and Tolerability of PSI-7851, a Novel Nucleotide Polymerase Inhibitor for HCV, Following Single and 3 Day Multiple Ascending Oral Doses in Healthy Volunteers and Patients with Chronic HCV Infection - (11/05/09)

* PHARMACOKINETICS/PHARMACODYNAMICS (PK/PD) OF COMBINATION RG7227 AND RG7128 THERAPY FROM INFORM-1 DEMONSTRATES SIMILAR EARLY HCV VIRAL DYNAMICS WHEN RG7227 IS COMBINED WITH EITHER PEG-IFN/RIBAVIRIN (SOC) OR RG7128 - (11/05/09)

* Boceprevir in Genotype 1 Null-Responders with Peg/RBV Lead-In - (11/05/09)

* Merck HCV Protease MK-7009 - (11/05/09)

* HCV/MSM Sex Transmission in HIV+ in New York City - (11/05/09)

* Combination Therapy With A Nucleoside Polymerase (RG7128) And Protease (RG7227/ITMN-191) Inhibitor In HCV: Safety, Pharmacokinetics, And Virologic Results From INFORM-1 - (11/04/09)

* Safety, Tolerability, Pharmacokinetics and Antiviral Activity following Single- and Multiple-Dose Administration of BMS- 650032, a Novel HCV NS3 Inhibitor, in Subjects with Chronic Genotype 1 HCV Infection - (11/04/09)

* High Sustained Virologic Response in Genotype 1 Null Responders to Peginterferon α-2b + Ribavirin When Treated with Boceprevir Combination Therapy Results From HCV Sprint-1 - (11/04/09)

* Once Daily Narlaprevir (SCH 900518) in Combination with Peginterferon alfa-2b/ Ribavirin for Treatment-Naive Patients with Genotype-1 Chronic Hepatitis C: Interim Results from the NEXT-1 Study - (11/04/09)

* BI 207127 is a potent HCV RNA polymerase inhibitor during 5 days monotherapy in patients with chronic hepatitis C - (11/04/09)

* Data Supporting Boceprevir Response Guided Therapy Presented at American Association for the Study of Liver Diseases (AASLD) Annual Meeting - Schering Plough press release - (11/01/09)

* Schering-Plough Reports Potent Antiviral Activity With Narlaprevir (SCH 900518), an Investigational, Once-Daily Protease Inhibitor for Hepatitis C - (11/01/09) Schering Plough press release

* GlobeImmune's Hepatitis C Therapeutic Vaccine Combined With Standard of Care Increases End of Treatment Response Rate by 15% - (11/01/09) press release

* Virological response and safety of BI 201335 protease inhibitor, peginterferon alfa 2a and ribavirin treatment of HCV genotype-1patients with compensated liver cirrhosis and non-response to previous peginterferon/ribavirin - (11/01/09)

* Schering hep C drug promising in Phase II study - (11/01/09)

* Telaprevir PROVE3 Final Results: treatment-experienced patients - (11/01/09)

* Boceprevir in Genotype 1 Null-Responders with Peg/RBV Lead-In - (11/01/09)

* Merck HCV Protease MK-7009 - (11/01/09)

* HBsAg Decline in HBeAg-Negative Patients Treated With Peginterferon Alfa-2a is Associated With Sustained Response up to 5 Years Post-Treatment: Patients with Continuous HBsAg Decline Starting Before Week 24 Achieve Highest Rates of Response - (11/01/09)